Updated Oct 28, 2026 · 12:56 UTC
RXRXRecursion Pharmaceuticals, Inc.
Health Care · United States · XNAS · biological products, (no diagnostic substances)
$4.02+6.58%last session · market early-hours
Market cap
$2.40b
real-world
Tokenized
$6k
<0.001% of the asset
Avg token price
$4.05
+0.81% vs real
Spot volume, 24h
$496
1 venues
Derivatives, 24h
—
Perp open interest
—
In DeFi
—
RXRX · Price
Token Real
EarningsNasdaq’s earnings calendar
Next earnings
Nov 4
estimated date · Sep 2026 quarter · EPS forecast −$0.24 (3 analysts)
Last earnings, Aug 5
−$0.25 EPS
−8.7% vs −$0.23 forecast · Jun 2026 quarter
Real marketRecursion Pharmaceuticals, Inc. Class A Common Stock
Last close
$4.05
Oct 27
Traded on Oct 27
$89.1m
Price now
$4.02
market early-hours
Where it trades24h volume by venue, as the exchanges report it · open interest and funding on the perpetuals
Spot · $496 · 1 venue
Ondo Stocks1 pair$496Derivatives · — · 0 venues
None yet
In DeFiPools and lending markets that hold these tokens
None found
Onchain versions2 tokens from 2 issuers
RXRXonOndo Assets$4.05$6k
RXRXcCoinbase——HoldersAddresses holding its tokens on each chain counted, each token counted and added, issuers’ own addresses left out · the value is what they hold onchain
BNB Chain18 holders$2k
Ethereum5 holders$4k
Solana4 holders$15Business 12 months to Jun 2026 · SEC EDGAR
Results
Revenue
$54.9m
−15% YoY
Operating income
−$544.0m
-992% margin
Net income
−$518.9m
-946% margin
EPS, diluted
−$0.97
Diluted shares
532m
+28% YoY
Cash and balance sheet
Free cash flow
−$352.3m
−642% of revenue
Net cash
$540.9m
$545.7m cash and securities, $4.8m debt
Quarterly
RevenueNet income
Valuation today’s market cap $2.40b · enterprise value $1.86b
EV / sales
33.9×